United States: 2018 Healthcare In Review

We have looked back over some of the headlines covering healthcare in 2018 for important issues facing healthcare facilities, practitioners, and patients. Here is our round-up:

1. The Opioid Epidemic. Both Tennessee and Mississippi enacted new regulations in 2018 to address the Opioid Epidemic. Federal law was enacted as well:

Tennessee. The following changes relating to opioid prescriptions went into effect on July 1, 2018: (1) limitations of supply and strength of the opioid prescription, (2) requirements that the pharmacy monitor the state's Controlled Substance Monitoring Database the first time a patient brings a prescription to a pharmacy and at least once every six months thereafter if the patient is refilling the prescription, (3) physician documentation requirements when prescribing opioids, and (4) elimination of pharmacist prohibitions when discussing the dangers of opioids with customers. These restrictions do not apply to opioid prescriptions for a three-day (or less) supply.

Mississippi. Effective October 29, 2018, new regulations apply to all individuals with prescriptive authority under Mississippi State Board of Medical Licensure. Such individuals must be registered with the Mississippi Prescription Monitoring Program (MPMP). Each provider must review the MPMP database when prescribing a Schedule II drug or opioid for acute, and/or chronic, non-cancerous, non-terminal pain. Further, each practitioner must review the MPMP database upon initial contact with all new patients and every 3 months thereafter on all patients prescribed, administered or dispensed controlled substances other than opioids. The amendments to the opioid regulations also include new documentation requirements for practitioners prescribing opioids, lowest effective dose limitations, exceptions for certain controlled substances, and specific refill prohibitions and other requirements.

The Federal Opioid Bill. On October 24, 2018, President Trump signed the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act. The SUPPORT Act includes comprehensive regulations to combat the opioid epidemic. Several significant provisions include:

Initial exams for new Medicare enrollees must include an opioid-use disorder screening and prescription history review.

The bill temporarily freezes Medicare payment at 2016 levels for specified spinal surgery outpatient procedures that are conducted in ambulatory surgical centers.

In general, prescriptions for controlled substances that are covered drugs under Medicare must be transmitted through electronic prescription programs.

2. HIPAA In Review. 2018 saw breaches affecting millions of patients. Also this year, Anthem, an affiliate of BlueCross BlueShield, settled with OCR for a breach occurring in 2015. The settlement includes a $16 million fine, the largest to date for HIPAA violations.

UnityPoint Health, a major health system in Iowa, reported a HIPAA breach affecting 1.4 million patients. It involved a phishing attack that sent emails to employees that appeared to be from a health executive within the system. This tricked some employees into sharing log-in credentials, enabling hackers to have access to various email accounts for over two weeks.

In Texas, 1.25 million records were exposed in a data breach of Employees Retirement System of Texas (ERS). Through a security coding error introduced on January 1, 2018, a function unintentionally enabled certain ERS members to view information about other members and in some cases, certain beneficiaries. The security malfunction was discovered in mid-August.

3. Fraud and Abuse.

Federal Opioid Enforcement Action. On Thursday, June 28, 2018, DHHS announced one of the largest health care fraud enforcement actions in history, resulting in more than $2 billion in fraudulent claims to federal health programs. The enforcement action involved over 601 charged defendants, including 165 doctors, nurses and other licensed health care professionals. Of these, the action involved 84 opioid cases relating to more than 13 million illegal opioid doses. The press release indicates that many of the prescriptions were never even purchased or distributed to patients.

$262 Million Settlement for Improper Inpatient Admissions. On September 25, 2018, Community Health Systems, Inc. ("CHS") announced that it reached a resolution and settlement agreement with the U.S. Department of Justice regarding its investigation into Health Management Associates, Inc.'s ("HMA") hospitals' billing federal healthcare programs for inpatient admissions following emergency room visits occurring between January 2008 and December 2012. According to statements from the federal Justice Department, HMA improperly pressured ER doctors to increase the number of inpatient admissions from emergency departments, even if these were not medically necessary. All activity involved in the investigation occurred prior to CHS's acquisition of HMA. The settlement agreement includes a payment of $262 million. The terms of the corporate integrity agreement should run through 2021.

4. Tennessee Legislative Updates

The 110th General Assembly of the Tennessee Legislature produced several new laws affecting hospitals, physicians and other healthcare providers:

SB2244 permits the commissioner of the Tennessee Department of Health to suspend the admission of any new patients or residents to any facility when the commissioner has a factual basis to believe the conditions in the facility are or are likely to be, harmful to the health, safety or welfare of a patient or resident. This regulation will apply to hospitals, ambulatory surgical treatment centers, nursing homes, etc.

SB1824 permits hospitals to require a maintenance of certification before granting privileges to a physician.

SB2513 requires the Tennessee Board for Licensing Health Care Facilities to create a process for recognizing hospitals with stroke-related designations.

SB2498 imposes certain requirements on individuals practicing ultrasound sonography in a nonclinical 3D/4D ultrasound boutique setting.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Sign Up
Gain free access to lawyers expertise from more than 250 countries.
Email Address
Company Name
Confirm Password
Mondaq Newsalert
Select Topics
Select Regions
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions